The French drug maker will work with Google's life sciences team to collect, analyze and understand information impacting diabetes.
The new entity will continue to work with other life sciences companies to move new technologies from early stage R&D to clinical testing.
The device that won't be marketed to consumers can measure the wearer's pulse, heartbeat rhythm, skin temperature, light exposure and noise levels.
Using sensors, software and data analysis tools, the two parties are looking to explain why multiple sclerosis progresses differently from patient to patient.
The pill contains tiny particles coated "magnetized" with antibodies that can spread throughout the body and then latch on to the abnormal cells.
Lift Labs will continue to sell its Liftware system, with Google enabling them to reach even more people living with Parkinson's or essential tremor.